4596 — Kubota Pharmaceutical Holdings Co Income Statement
0.000.00%
Last trade - 00:00
- ¥4bn
- ¥2bn
- ¥40m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 37.8 | 0 | 8.25 | 39.9 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 2.43 | 28.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 3,288 | 2,522 | 2,585 | 2,046 | 1,544 |
Operating Profit | -3,288 | -2,484 | -2,585 | -2,038 | -1,504 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3,105 | -2,437 | -2,616 | -2,016 | -1,490 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3,066 | -2,437 | -2,616 | -2,016 | -1,490 |
Net Income Before Extraordinary Items | |||||
Net Income | -3,066 | -2,437 | -2,616 | -2,016 | -1,490 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3,066 | -2,437 | -2,616 | -2,016 | -1,490 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -73.1 | -58.2 | -58.8 | -42.4 | -24.8 |
Dividends per Share |